Camp4, Alnylam partner to identify liver disease targets with machine learning

Camp4 Therapeutics Corp. (Cambridge, Mass.) will deploy its Gene Circuitry Platform under a deal with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to identify new targets for an undisclosed rare liver disease.

CAMP4's platform uses machine learning to create a computational model of all of the different combinations of signaling molecules and transcription factors that come together to regulate the expression of each gene in a cell type. It also maps how those molecular components change over time (see "Gene Control Goals")...